Interestingly, dasatinib has been shown to reduce the expression of ALDH1A1, leading to potentiation of gemcitabine in a gemcitabine-resistant pancreatic cancer cell line [520]. This evidence concerns the gene ALDH1A1 and familial pancreatic carcinoma.